A galactagogue is any substance taken to boost breast milk production, and the category includes both prescription drugs and herbal remedies that have been used across cultures for centuries. The two most studied pharmaceutical options are domperidone and metoclopramide, while popular herbal choices include fenugreek, moringa, shatavari, and silymarin. Despite how widely these substances are recommended in online parenting communities and even by some healthcare providers, the clinical evidence behind most of them is surprisingly thin, and a few carry real safety concerns that rarely get mentioned alongside the enthusiastic testimonials.
How Milk Production Actually Works
Breast milk production is driven primarily by the hormone prolactin, which is released from the pituitary gland. Under normal conditions, the brain keeps prolactin under tight control through dopamine, a chemical messenger released from a specific cluster of neurons in the hypothalamus. Dopamine acts as a brake on prolactin: as long as dopamine levels stay high, prolactin stays low and milk production stays modest.1Comprehensive Physiology. Neuroendocrine Regulation of Lactation and Milk Production The physical act of a baby nursing or a pump removing milk sends nerve signals that temporarily lift this dopamine brake, allowing prolactin to surge and the breasts to make more milk. That feedback loop is the foundation of the whole system.
Most pharmaceutical galactagogues work by interfering with dopamine’s ability to suppress prolactin. By blocking dopamine receptors, these drugs let prolactin rise higher than it otherwise would, signaling the breast tissue to produce more milk. Herbal galactagogues, by contrast, have proposed mechanisms that are much less clear. Some may affect prolactin; others might improve blood flow, alter hormone metabolism, or work through pathways no one has identified yet. In many cases, researchers simply do not know why a particular herb seems to help some women produce more milk.
Pharmaceutical Galactagogues
Domperidone and metoclopramide are the two drugs most commonly prescribed off-label to increase milk supply. Neither was originally designed for this purpose. Both are anti-nausea medications that happen to block dopamine receptors, and that dopamine-blocking effect is what raises prolactin.
Domperidone has the stronger track record in lactation research. In a randomized, placebo-controlled trial involving mothers of premature newborns, women taking domperidone saw their milk production rise by about 45% over a week, compared with roughly 17% in the placebo group.2PubMed Central. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial A broader review of blinded trials found that every identified domperidone study showed a significant difference in milk output between the treatment and placebo groups.3PubMed Central. A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding That consistency is unusual for galactagogue research, where positive results are often unreliable.
Metoclopramide has a weaker showing. Of six blinded, placebo-controlled trials identified in one review, only one found a significant increase in milk production compared to placebo.4PubMed Central. A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding Metoclopramide also crosses the blood-brain barrier more easily than domperidone, which means it is more likely to cause side effects in the central nervous system, including drowsiness, anxiety, and in rare cases, movement disorders. Animal research has raised additional concerns: in rat pups exposed to metoclopramide through their mothers’ milk, the drug altered expression of brain proteins involved in dopamine signaling and nerve cell growth in the prefrontal cortex.5PubMed. Metoclopramide use to induce lactation can alter DRD2 and BDNF in the prefrontal cortex of offspring Whether that translates to effects in human infants is unknown, but the finding gives researchers pause.
Cardiac Safety Concerns with Domperidone
Domperidone’s relative effectiveness comes with a significant caveat that often gets lost in conversations about breastfeeding support. The drug can affect heart rhythm. Laboratory studies have clearly shown that domperidone inhibits a specific type of ion channel in the heart at concentrations achievable through normal clinical dosing, and this inhibition can prolong the interval between heartbeats in a way that makes dangerous arrhythmias more likely.6PubMed. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine In large studies of patients using domperidone for digestive problems, the drug was linked to cases of abnormal heart rhythm and sudden cardiac death, with risk appearing higher in women.7PubMed. Use of domperidone as a galactagogue drug: a systematic review of the benefit-risk ratio
The cardiac risk appears to be dose-dependent and is amplified by certain conditions. People who already have a prolonged QT interval, who take other medications that slow the same heart channel, or who have electrolyte imbalances are at higher risk.8PubMed. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine This is why domperidone is not approved for any use in the United States, though it remains available by prescription in Canada, Australia, the UK, and many other countries. When prescribed for lactation, doctors typically use the lowest effective dose and recommend a baseline electrocardiogram for women with risk factors.
It is worth noting that the cardiac safety data come primarily from populations using domperidone for gastrointestinal conditions, where patients tend to be older and sicker than the typical breastfeeding mother. Whether the risk profile looks the same in young, otherwise healthy postpartum women is an open question, but the biological mechanism of action on the heart is not population-dependent. The ion channel effect happens regardless of who takes the drug.
Infant Exposure Through Breast Milk
One practical question that comes up for any breastfeeding medication is how much of the drug reaches the baby through milk. Domperidone performs well on this front. Very little of the drug passes into breast milk, with the relative infant dose estimated at roughly 0.01% to 0.04% of the maternal dose.9Australian Prescriber. Drugs affecting milk supply during lactation More precisely, at a typical maternal dose of 30 mg per day, the estimated relative infant dose is about 0.012%.10Ochsner Journal. A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding That is far below the threshold where you would expect any pharmacological effect in the infant. Metoclopramide transfers into breast milk more readily, and the risk of neurological side effects in the baby, though still low in absolute terms, is considered higher than with domperidone.11Australian Prescriber. Drugs affecting milk supply during lactation
Herbal Galactagogues
The herbal side of the galactagogue world is vast. Dozens of plants across global traditions are used to promote milk production, but the ones with any clinical trial data behind them are few. Fenugreek, moringa, shatavari (a species of asparagus native to South Asia), and silymarin (from milk thistle) are the most commonly studied.
Fenugreek is probably the most popular herbal galactagogue worldwide and has the most research. A network meta-analysis combining data from four trials found that fenugreek significantly increased breast milk volume compared to placebo.12PubMed. Effectiveness of fenugreek as a galactagogue: A network meta-analysis That sounds encouraging, but a closer look at the broader literature reveals contradictory results. Some trials show meaningful increases in milk production; others show only trivial differences from placebo.13PubMed Central. The Effect of Herbal Tea Containing Fenugreek Seed on the Signs of Breast Milk Sufficiency in Iranian Girl Infants The same network analysis also found that fenugreek’s effect was substantially inferior to two other plant-based comparators, suggesting it may not even be the best herbal option for those inclined toward botanical approaches.14PubMed. Effectiveness of fenugreek as a galactagogue: A network meta-analysis
Moringa leaf has drawn attention in Southeast Asia and parts of Africa. A systematic review found that a small daily dose of moringa increased breast milk volumes, though the evidence came from a limited number of studies and results were inconsistent in animals.15Wiley Online Library. The impact of Moringa oleifera leaf supplementation on human and animal nutrition, growth, and milk production: A systematic review Shatavari has traditional roots in Ayurvedic medicine and has recently gained traction among researchers. A randomized, placebo-controlled trial found that women taking shatavari root extract had significantly higher milk volume at 72 hours postpartum and shorter time to breast fullness after feeding.16PubMed. Shatavari (Asparagus racemosus Willd) root extract for postpartum lactation: A randomised, double-blind, placebo-controlled study A separate trial using a shatavari-based product confirmed both of those effects, with a statistically meaningful difference in total milk expressed.17PubMed Central. Use of Shavari Bar® Improves Breast Milk Output: A Double-Blind, Prospective, Randomized, Controlled Clinical Study
Why the Evidence Remains Weak
A recurring theme across galactagogue research is that even when individual trials report positive results, systematic reviews keep finding the evidence insufficient to make formal recommendations. A comprehensive review of herbal galactagogue trials identified multiple problems: small sample sizes, poor randomization, loosely defined eligibility criteria, use of multi-herb mixtures that make it impossible to isolate a single ingredient’s effect, and inconsistent breastfeeding practices among participants. The authors concluded that no recommendation could be made for any herbal galactagogue.18PubMed. Systematic review of the efficacy of herbal galactogogues A separate review covering both pharmaceutical and herbal galactagogues reached a similar verdict, describing a “dearth of high-quality clinical trials and mixed results.”19PubMed Central. A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding
Part of the problem is that measuring milk production accurately is harder than it sounds. The two most widely used techniques are test-weighing (weighing the infant before and after a feeding) and a method using deuterium oxide, a stable isotope of water that can track how much milk an infant is consuming over days without disrupting normal feeding.20PubMed Central. The Deuterium Oxide Dilution Method to Quantify Human Milk Intake Volume of Infants: A Systematic Review Many galactagogue trials instead rely on expressed milk volume, which doesn’t capture how much the baby actually gets during direct breastfeeding and varies depending on pump type, technique, and timing. That measurement noise makes small effects easy to miss and false positives easy to generate.
Another difficulty is the placebo effect. Mothers who believe a supplement is helping them may nurse more frequently or more confidently, which in turn genuinely increases milk production through the normal demand-supply feedback loop. Separating the biological effect of a substance from the behavioral change it triggers is methodologically challenging, and many trials are not designed well enough to do it.
Before Reaching for a Galactagogue
Perceived low milk supply is one of the most common reasons mothers stop breastfeeding earlier than planned, but actual insufficient production is less common than many parents believe. A baby who fusses frequently, feeds often, or has a growth spurt can easily convince a parent that the supply is inadequate when it is perfectly normal. Clinical lactation guidelines emphasize that the first step is objective assessment: tracking diaper output, weight gain, and feeding frequency before concluding that supply is truly low.
When supply genuinely is insufficient, the most effective intervention is not a pill or a tea but more frequent and thorough milk removal. Increasing the number of feedings or pumping sessions and ensuring the breast is well drained at each session sends stronger signals through the prolactin feedback loop. Galactagogues are generally considered an add-on after optimizing these behavioral factors, not a replacement for them.21PubMed Central. Principles for maintaining or increasing breast milk production
There are also anatomical and hormonal reasons why some women produce less milk regardless of how frequently they nurse. A retrospective survey of women reporting insufficient milk production found that roughly two-thirds had at least one marker of breast hypoplasia, such as widely spaced breasts or a lack of breast growth during pregnancy.22PLOS ONE. Breast hypoplasia markers among women who report insufficient milk production: A retrospective online survey Conditions like polycystic ovary syndrome, thyroid disorders, retained placental fragments, and prior breast surgery can all impair milk production in ways that a galactagogue is unlikely to fully overcome. If one of these underlying issues is present, treating it directly is more productive than layering supplements on top of it.
Quality and Contamination Risks with Herbal Products
Herbal galactagogues occupy a regulatory gray zone in most countries. In the United States, they are sold as dietary supplements, which means they do not undergo the premarket approval process that pharmaceutical drugs do. Manufacturers are responsible for their own quality control, and the results of that self-regulation are uneven.
One concern that applies to all herbal products, not just galactagogues, is heavy metal contamination. A large-scale analysis testing over 1,700 herbal medicine samples from around the world found that roughly 30% exceeded at least one heavy metal limit set by pharmacopeia standards, with lead and cadmium being the most common offenders.23PubMed Central. Heavy Metal Contaminations in Herbal Medicines: Determination, Comprehensive Risk Assessments, and Solutions For a general population, trace amounts of lead in an herbal supplement are concerning but often tolerable. For a breastfeeding mother, where contaminants can transfer to the infant, the stakes are higher. Third-party testing certifications (like USP or NSF) provide some assurance, but they are voluntary and many galactagogue products don’t carry them.
Dosing is another issue. Fenugreek, for example, is sold in capsules, teas, powders, and tinctures at widely varying concentrations. The dose used in clinical trials may bear no resemblance to what is in a particular off-the-shelf product. Since there are no standardized dosing guidelines for herbal galactagogues, two women taking “fenugreek” could be consuming wildly different amounts of active compounds.
Oxytocin and Other Experimental Approaches
Beyond the dopamine-blocking drugs, a few other substances have been explored as galactagogues. Oxytocin, the hormone responsible for the milk let-down reflex (the physical release of milk already produced in the breast), has been tried as a nasal spray. An early study gave oxytocin intramuscularly to 100 nursing mothers for two days, then switched half of them to an oxytocin nasal spray while the other half served as controls. The results were not dramatically different between groups, though the researchers noted that the spray group included the more difficult cases and may have derived some benefit.24PubMed Central. MILK LET-DOWN-The Use of Intranasal Oxytocin for Nursing Mothers Oxytocin’s role in lactation is to eject milk that has already been made, not to stimulate new production, so it addresses a different bottleneck than prolactin-boosting drugs. For mothers who produce adequate milk but have difficulty with let-down, it could theoretically be useful, but the research remains too thin to draw firm conclusions.
Growth hormone and its related peptides have been studied primarily in the dairy industry rather than in human medicine. In dairy cows, recombinant bovine somatotropin interacts with insulin to increase milk protein synthesis and overall yield, an effect mediated partly through insulin-like growth factor-I.25PubMed. Effects of insulin, recombinant bovine somatotropin, and their interaction on insulin-like growth factor-I secretion and milk protein production in dairy cows These hormonal pathways exist in humans too, but the ethical and safety considerations of manipulating growth hormone in breastfeeding women are substantial, and no one is seriously proposing it as a clinical intervention.
Galactagogues in Animal Agriculture
The galactagogue concept extends well beyond human breastfeeding. Dairy farming has its own long history of attempting to increase milk yields through feed additives, hormones, and management practices. The use of recombinant bovine somatotropin in cattle is essentially a pharmaceutical galactagogue strategy, and it is effective: treated cows produce significantly more milk, partly because the hormone redirects nutrients toward the mammary gland and partly because it promotes the growth and maintenance of milk-producing tissue.26PubMed. Effects of insulin, recombinant bovine somatotropin, and their interaction on insulin-like growth factor-I secretion and milk protein production in dairy cows The technology is approved in the United States but banned in the European Union, Canada, and several other countries, largely over animal welfare concerns and consumer unease rather than demonstrated risks to people drinking the milk.
Herbal approaches appear in veterinary contexts as well. Moringa leaf, for instance, has been studied as a feed supplement for goats and cows, though the results have been inconsistent, with some studies showing increased milk production and others showing no effect.27Wiley Online Library. The impact of Moringa oleifera leaf supplementation on human and animal nutrition, growth, and milk production: A systematic review The parallel between human and animal galactagogue research is interesting: in both cases, there are a handful of substances with genuine pharmacological effects on milk production, a much larger group of traditional remedies with ambiguous evidence, and persistent pressure from the people who need the milk to find something that works.
Who Actually Benefits from Galactagogues
The population most likely to benefit from pharmaceutical galactagogues is mothers of premature infants who need to establish a supply while their baby is too small or too sick to nurse effectively. These women are pumping rather than breastfeeding, often under stressful conditions, and the normal demand-driven feedback loop is weakened. The domperidone trial that showed a 45% increase in milk output specifically enrolled mothers of preemies.28PubMed Central. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial Adoptive mothers attempting to induce lactation without having been pregnant represent another group for whom galactagogues may play a meaningful role, since they are starting from a baseline of zero milk production and need pharmacological help to establish a prolactin response.
For the average mother with a healthy term infant who feels her supply is low, the evidence suggests that galactagogues are a less important intervention than ensuring frequent, effective milk removal and addressing any latch or positioning issues. The risk-to-benefit calculation shifts when the underlying problem is technique rather than biology. A fenugreek supplement is unlikely to cause harm in most women (aside from a distinctive maple-syrup smell in sweat and urine that can be alarming if unexpected), but it is also unlikely to solve a problem that has its roots in infrequent feeding or a shallow latch. The most honest summary of the field is that galactagogues have a real but narrow role, and that the enthusiasm surrounding them in popular breastfeeding culture outpaces the evidence by a wide margin.